MedPath

Sancuso

These highlights do not include all the information needed to use Sancuso (Granisetron Transdermal System) safely and effectively. See full prescribing information for Sancuso. Sancuso (Granisetron Transdermal System) Initial U.S. Approval: 2008

Approved
Approval ID

9aed2020-1827-4f13-99df-191c492c11f9

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 30, 2009

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

granisetron

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54868-5985
Application NumberNDA022198
Product Classification
M
Marketing Category
C73594
G
Generic Name
granisetron
Product Specifications
Route of AdministrationTRANSDERMAL
Effective DateNovember 1, 2011
FDA Product Classification

INGREDIENTS (1)

GRANISETRONActive
Quantity: 3.1 mg in 24 h
Code: WZG3J2MCOL
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Sancuso - FDA Drug Approval Details